Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB, a Nasdaq Stockholm-listed biopharmaceutical developer of novel Parkinson’s disease treatments, will publish its year-end 2025 report on February 25, 2026, at 07:00 CET. The Gothenburg-based company, led by CEO Kristina Torfgård, continues to advance a pipeline spanning late-stage clinical assets and early-stage candidates targeting motor and neuropsychiatric complications in Parkinson’s and other neurodegenerative disorders.
On the same day at 10:00 CET, IRLAB’s management team will present the year-end results via a digital webcast in Swedish, followed by a Q&A session for investors and other stakeholders. The live-streamed presentation, along with the interim report and a recorded version of the webcast, will be made available on the company’s website and YouTube channel, enhancing transparency and accessibility around its financial and R&D progress.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Hold with a SEK1.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Sweden-based biopharmaceutical company focused on discovering and developing transformative treatments for all stages of Parkinson’s disease and related neurodegenerative disorders. Originating from Nobel Laureate Prof Arvid Carlsson’s research on neurotransmitter disorders, the company’s pipeline includes Mesdopetam for levodopa-induced dyskinesias in preparation for Phase III, Pirepemat in Phase IIb for reducing fall frequency, IRL757 in Phase I for apathy, and two preclinical programs, IRL942 and IRL1117, all generated by its proprietary Integrative Screening Process platform.
Average Trading Volume: 233,596
Technical Sentiment Signal: Sell
Current Market Cap: SEK155.9M
For an in-depth examination of IRLAB.A stock, go to TipRanks’ Overview page.